Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $31.92, but opened at $30.53. Moderna shares last traded at $32.53, with a volume of 7,862,619 shares changing hands.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on MRNA shares. JPMorgan Chase & Co. lowered their price objective on Moderna from $59.00 to $45.00 and set an "underweight" rating for the company in a research report on Tuesday, November 26th. Needham & Company LLC reiterated a "hold" rating on shares of Moderna in a report on Friday, November 8th. HSBC upgraded shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 price objective on the stock in a report on Monday, November 18th. Bank of America lowered their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research note on Tuesday, February 11th. Finally, Wolfe Research began coverage on shares of Moderna in a research note on Friday, November 15th. They issued an "underperform" rating and a $40.00 price target on the stock. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Moderna has an average rating of "Hold" and a consensus price target of $61.58.
Check Out Our Latest Analysis on Moderna
Moderna Stock Up 8.3 %
The stock has a market cap of $13.75 billion, a PE ratio of -6.14 and a beta of 1.59. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average of $38.61 and a 200 day moving average of $53.82.
Insider Buying and Selling at Moderna
In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares of the company's stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by insiders.
Hedge Funds Weigh In On Moderna
Several institutional investors have recently added to or reduced their stakes in MRNA. FMR LLC grew its stake in shares of Moderna by 7.4% in the 4th quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after purchasing an additional 1,282,469 shares during the last quarter. State Street Corp grew its position in Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company's stock valued at $1,125,899,000 after buying an additional 1,823,276 shares during the last quarter. Theleme Partners LLP increased its stake in Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after buying an additional 72,028 shares during the period. Geode Capital Management LLC raised its position in Moderna by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 7,241,354 shares of the company's stock worth $300,219,000 after buying an additional 171,774 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock worth $349,166,000 after acquiring an additional 906,114 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.
About Moderna
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
